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Abstract
Context: Prostate cancer is the second leading cause of cancer in men, second to skin cancer and the second
leading cause of cancer related deaths second only to lung cancer. With the development of the PSA test
prostate cancer is getting detected in its early stages, thought to be 7 years earlier than before PSA. The
treatments for Prostate CA vary, but for those patients with low grade and early stage cancer one treatment
option is that of Brachytherapy. These patients tend to suffer fewer complications than those who have had a
radical or partial prostatectomy; however they can still develop significant urinary, erectile and rectal
symptoms. Objective: The goal of this study is to look at the symptoms of patient's pre and then 5 years post
brachytherapy and compare the symptoms. My hope is that majority of patients will worsen their symptom
scores by only a small margin, This research will also allow the surgens at The Urology Clinic to better assess
their patients outcomes. Setting: Data was collected at the Urology Clinic in' Portland through a patient
survey and from the brachytherapy database at the advanced urology center in Emanuel Hospital in Portland,
OR. Method: A retrospective chart review and brief survey sent to patients who have had Brachytherapy. The
review included those patients who received treatment for prostate cancer from 8/1996 through 5100, and Dr.
McCoy was the Urologist on the case. These dates were chosen to give the best chance' of obtaining 5 year
follow-up data. The Brachytherapy Database in the Advanced Urology Department of Emanuel was utilized to
obtain the majority of data. The remaining information was obtained through a brief follow-up survey that was
sent out to the 138 patients of Dr. McCoy's. The five year data was then compiled and pretreatment and post-
treatment symptom comparisons were made based on patients risk factors (PSA, Gleason Score, Age) and
whether or not the patients failed the treatment (30r > successive rises in PSA). Results: General Outcomes
The resuits of the five year post PSA values were addressed (see table 2 and figure 9). Due to patients being
lost to follow-up or death, we were only able to obtain the five year post-treatment PSA values for 63.8%
(n=88) of our patients. Of the 88 , patients, only one experienced an increase in PSA from pre-treatment
(5.2ng/ml) to a five year post-treatment PSA C14.1ng/ml). Majority of patients experienced an increase in
their AUA scores, the mean pre-treatment AUA score was 7.04 and the mean post-treatment AUA score was
11.52, a difference of 4.48 (see table 3). Graph B and C depict the urinary and sexual outcomes. About a 40%
decrease in sexual potency was seen post':treatment (table 3). There was a 30% increase in rectal symptoms
from pre- vs. post-treatment (table 3), L~w vs. High Risk The low risk PSA population comprised 81.8% of
the study population. "In terms of PSA reduction, the low risk group did not experience as large of a decrease
in PSA values that those of the High risk group experienced in the first 3 years; however, both groups managed
to experience significant PSA reductions over the 5 year term. When risk was categorized based on pre-PSA,
Gleason score and extra-prostatic extension probability, there were no real differences between the low and
high risk groups of AUA scores (low risk mean pre/post AUA= 6.88/11.49 ±1, high risk mean pre/post
AUA=7.73/l1.63 ±1) (see table 4). Significant improvement in SHIM scores of patients in both the low and
high risk groups, but due to the difference in population size it is difficult to determine. The rectal symptoms
in the low risk group, due to the larger population, were more varied. The post-rectal symptom data supported
the development of bleeding in 1-2% of the low risk g~oup and about 6% in the high risk group. The
development of proctitis was insignificant. It was difficult to determine from the results whether PSA or
Gleason score was a better determinate for how patients would tolerate the treatment. (Low vs. High PSA:
Chi-square=3.145, df=1, p=0.076; Gleason: Chi square= 0.006, df=1, p=0.936). To depict extra-prostatic
extension vs. SHIM a nonparametric analyses (Mann-Whitney V) was used, (1iee figure 12) and the results
appeared to be significant (Mann-Whitney V = 1120.50, p=O.017). The data for extension and ADA again
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showed a similar increase in ADA post-treatment. There was no difference between the low and high risk
groups in terms of the rectal symptoms. Mono- vs. Multi-therapy The addition of other therapies did not yield
an obvious benefit over mono-therapy (see table 5). The use of a two-sample t-test, found no significant
difference between the two groups of patients (t=0.007, df=75, p==0.995). PSA was affected in the two
groups and this showed a significant difference. Patients in the multi-therapy group experienced a greater
decrease in PSA values compared to the monotherapy group. (t=2.783, df=85, p=0.007). Mann-Whitney U
test p=0.006. Sexual function was affected by the type of therapy. Those who received multi-therapy
experienced more improvement than those with mono-therapy (Chi-square=4.420, df==1, p=0.036). -
Erectile Dysfunction Medications In- this study, 20% (n=18) of the study population was admittedly taking -
one of these medications. There were no significant _ differences in outcomes between patients who took ED
medications and those who -aid -not (chi-square=2.156, df=1, p=0.142). Conclusions: The treatment of
prostate cancer with the use of brachytherapy, in this study has been shown to yield minimal risk in regards to
patients developing urinary, sexual and rectal symptoms. The general outcome of this study population
resulted in 98.9% of the 88 study patients to have a decrease in their PSA, 20-40% increase in AVA scores,
about a 20% improvement in SHIM scores and about 25% of the patients developed rectal symptoms with
11-12% of those as proctitis. From this we can conclude that patients are more likely to develop urinary
symptoms post brachytherapy than ED, or rectal symptoms. When the patients were divided into Low and
High Risk groups by PSA, Gleason score, and then by probability of developing extra-prostatic extension,
calculated from the Partin Table, there was no significant difference between the PSA and Gleason score
however there does tend to be a trend for the high risk groups to improve more than expected by random
error. The use of extra-prostatic extension does prove to be an indicator of potency. Along these same lines;
there did not appear to be any real advantage to those patients who received external beam, hormone therapy
or a combination of the two along with brachytherapy versus those who just received brachytherapy as a
mono therapy. There are many alternative studies that could be applied to this topic.
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Abstract: 
Context: Prostate cancer is the second leading cause of cancer in men, second to skin 
cancer and the second leading cause of cancer related deaths second only to lung cancer. 
With the development of the PSA test prostate cancer is getting detected in its early 
stages, thought to be 7 years earlier than before PSA. The treatm~hts for Prostate CA 
vary, but for those patients with low grade and early stage cancer one treatment option is 
that of Brachytherapy. These patients tend to suffer fewer complications than those who 
have had a radical or partial prostatectomy; however they can still develop significant 
urinary, erectile and rectal symptoms. Objective: The goal of this study is to look at the 
symptoms of patient's pre and then 5 years post brachytherapy and compare the 
symptoms. My hope is that majority of patients will worsen their symptom scores by 
only a small margin, This research will also allow the surgepns at The Urology Clinic to 
better assess their patients outcomes. Setting: Data was collected at the Urology Clinic 
in' Portland through a patient survey and from the brachytherapydatabase at the advanced 
urology center in Emanuel Hospital in Portland, OR. Method: A retrospective chart 
review and brief survey sent to patients who have had Brachytherapy. The review 
included those patients who received treatment for prostate cancer from 8/1996 through 
5100, and Dr. McCoy was the Urologist on the case. These dates were chosen to give the 
best chance' of obtaining 5 year follow-up data. The Brachytherapy Database in the 
Advanced Urology Department of Emanuel was utilized to obtain the majority of data. 
The remaining information was obtained through a brief follow-up survey that was sent 
out to the 138 pa~ients of Dr. McCoy's. The five year data was then compiled and pre-
treatment and post-treatment symptom comparisons were made based on patients risk 
factors (PSA, Gleason Score, Age) and whether or not the patients failed the treatment 
(30r > successive rises in PSA). Results: General Outcomes The resuits of the five 
year post PSA values were addressed (see table 2 and figure 9). Due to patients being 
lost to follow-up or death, we were only able to obtain the five year post-treatment PSA 
values for 63.8% (n=88) of our patients. Of the 88 , patients, only one experienced an 
increase in PSA from pre-treatment (5.2ng/ml) to a five year post-treatment PSA 
C14.1ng/ml). Majority of patients experienced an increase in their AUA scores, the mean 
pre-treatment AUA score was 7.04 and the mean post-treatment AUA score was 11.52, a 
difference of 4.48 (see table 3). Graph B and C depict the urinary and sexual outcomes. 
About a 40% decrease in sexual potency was seen post':treatment (table 3). There was a 
30% increase in rectal symptoms from pre- vs. post-treatment (table 3), L~w vs. High 
Risk The low risk PSA population comprised 81.8% of the study population. "In terms 
of PSA reduction, the low risk group did not experience as large of a decrease in PSA 
values that those of the High risk group experienced in the first 3 years; however, both 
groups managed to experience significant PSA reductions over the 5 year term. When 
risk was categorized based on pre-PSA, Gleason score and extra-prostatic extension 
probability, there were no real differences between the low and high risk groups of AUA 
scores (low risk mean pre/post AUA= 6.88/11.49 ±1, high risk mean pre/post 
AUA=7.73/l1.63 ±1) (see table 4). Significant improvement in SHIM scores of patients 
in both the low and high risk groups, but due to the difference in population size it is 
difficult to determine. The rectal " symptoms in the low risk group, due to the larger 
popUlation, were more varied. The post-rectal symptom data supported the development 
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of bleeding in 1-2% of the low risk g~oup and about 6% in the high risk group. The 
development of proctitis was insignificant. It was difficult to determine from the results 
whetherPSA or Gleason score was a better determinate for how patients would tolerate 
the treatment. (Low vs. High PSA: Chi-square=3.145, df=1, p=0.076; Gleason: Chi-
square=0.006, df=1, p=0.936). To depict extra-prostatic extension vs. SHIM a 
nonpal'ametric analyses (Mann-Whitney V) was used, (1iee figure 12) and the results 
appeared to be significant (Mann-Whitney V = 1120.50, p=O.017). The data for 
extension and ADA again showed a similar increase in ADA post-treatment. There was 
no difference between the low and high risk groups in terms of the rectal symptoms. 
Mono- vs. Multi-therapy The addition of other therapies did not yield an obvious 
benefit over mono-therapy (see table 5). The use of a two-sample t-test, found no 
significant difference between the two groups of patients (t=0.007, df=75, p==0.995). PSA 
was affected in the two groups and this showed a significant difference. Patients in the 
multi-therapy group experienced a greater decrease in PSA values compared to the mono-
therapy group. (t=2.783, df=85, p=0.007). Mann-Whitney U test p=0.006. 
Sexual function was affected by the type of therapy. Those who received multi-therapy 
experienced more improvement than those with mono-therapy (Chi-square=4.420, df==1, 
p=0.036). - Erectile Dysfunction Medications In- this study, 20% (n=18) of the study 
population was admittedly taking -one of these medications. There were no significant 
_ differences in outcomes between patients who took ED medications and those who -aid 
-not (chi-square=2.156, df=1, p=0.142). Conclusions: The treatment of prostate cancer 
with the use of brachytherapy, in this study has been shown to yield minimal risk in 
regards to patients developing urinary, sexual and rectal symptoms. The general outcome 
of this study population resulted in 98_9% of the 88 study patients to have a decrease in 
their PSA, 20-40% increase in AVA scores, about a 20% irriprovement in SHIM scores 
and about 25% of the patients developed rectal symptoms with 11-12% of those as 
proctitis. From this we can conclude that patients are more likely to develop urinary 
symptoms post brachytherapy than ED, or rectal symptoms. When the patients were 
divided into Low and High Risk groups by PSA, Gleason score, and then by probability 
of developing extra-prostatic extension, calculated from the Partin Table, there was no 
significant difference between the PSA and Gleason score however there does tend to be 
a trend for the high risk groups to improve more than expected by random error. The use 
of extra-prostatic extension does prove to be an indicator of potency. Along these same 
lines; there did not appear to be any real advantage to those patients who received 
external beam, hormone therapy or a combination of the two along with brachytherapy-
versus those who just received brachytherapy as a mono therapy. There are many 
alternative studies that could be_ applied to this topic. - -
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An Assesslnent of Patient Symptoms Pre and Post Brachytherapy 
treatment for Prostate Cancer, Focusing on those Patients who are 
5 years post treatment. 
Introduction 
Rational for Study 
Long term post-prostate brachytherapy data has not been acquired for the patients 
of The Urology Clinic in Portland, Oregon. The goal of this study is to look at the 
symptoms relating to urinary,· sexual and rectal function of these patients pre-
brachytherapy and compare those to syrriptoms of these same patients 5 years post-
brachytherapy for prostate cancer. The four questions addressed in this study are; 
1) Comparing general outcomes ofthe population looking to see whether or ITot 
the patients' symptoms improved. 
2) Which is a better predictor of low and high risk patients in regards to how 
patients do symptomatically over a 5 year period: PSA, Gleason score, or the 
result of the Partin table for the probability of extra-prostatic extension? 
3) Comparing the outcomes of patients who receiv'ed brachytherapy as a mono-
therapy versus those patients who received brachytherapy along with another 
treatment such as external beam radiation, hormone therapy or both. Is there any · 
significant benefit of multiple treatments over mono-therapy 
4) Were the outcomes of the sexual symptoms in those patients who received 
erectile dysfunction medications for impotence significantly different to those 
who did not? 
1 
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Hx Prostate Cancer 
Prostate cancer is the second leading cause of cancer in men, second to skin 
cancer, and the second leading cause of cancer related deaths second only to lung 
cancer.1,2 In 2001, in the United States there were about 198,000 cases of prost' ate cancer 
diagnosed and about 31,500 resulting deaths. !' 2 It has been found that more than forty 
percent of men over the age of fifty were found to have prostate cancer on autopsy. The 
majority of the disease found on autopsy was small, contained within the prostate and did 
not elicit any reported symptoms. The incidence of prostate cancer increases with age, 
being Black, or having a family history of a first ,degree relative with prostate cancer. It 
is also suspected that diet plays a role. New studies are suggesting that the BRCA2 gene 
for breast cancer is also linked to prostate cancer. 3 
Anatomy of Prostate Gland 
The prostate gland is a walnut sized gland located at the proximal end of the 
urethra just distal to the bladder neck in an area called the prostatic urethra. The prostate 
gland secretes a thin, slightly alkaline solution that is mixed with ejaculate from the 
seminal vesicles and is then excreted into the prostatic urethra. The gland is composed of 
. an anterior lobe, a median lobe, and two lateral lobes. ., 
Inflammation of the prostate, also known as prostatitis, can lead to a variety of 
urinary symptoms, for example causing dysuria, difficulty starting and stopping the 
stream of urine, pain with ejaculation, or blood in urine or ejaculate. Prostatitis can also 
present with low back pain and or testicular pain. It can often cause an elevation in the 
prostate specific antigen (PSA) readings. If the patient does present with urinary 
2 
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symptoms, an elevated PSA, and · has a negative digital reCtal examination (DRE) , it is 
common to do a trans-rectal ultrasound (TRUS) guided biopsy of the prostate and to treat 
prophylacticly with antibiotics while waiting for the pathology report. Often a biopsy is 
the only way to detect prostate cancer and is the gold standard. 
\ 
Prostate Cancer Specifics 
The prostate as described above is broken into lobes and zones, the 
peripheraillateral (65%), anterior or center (25%) and posterior or transitional (5-10%) 
zones.4 The majority of prostate cancers arise in the peripheral zone which can be 
detected with a DRE. Fortunately prostate cancer is a fairly slow growing cancer. The 
staging of prostate cancer is diagnosed, using PSA, DRE and TRUS guided biopsy to 
. ..
take tissue from the prostate which is then evaluated with the tumor-node-metastasis 
(TNM) staging system and Gleason score (refer to Figures 1 and 2). The Gleason score 
is a tool which determines the aggressiveness of a prostate tumor. It is broken down into 
patterns which are based on a 1-5 scale. Patterns 1 and 2 represent well differentiated 
cells, which mean the cells have a normal appearance and function. Pattern 3 is 
moderately-differentiated and Patterns 4 and 5 represent poorly differentiated cells, 
which lack the abil.ity to function properly in the prostate, often forming tumors or these 
cells can break off and metastasize to other areas of the body. 
When the Gleason score is written it is the sum · of the two most prominent 
Gleason patterns. For example, a 3+4=7 Gleason score has a better prognosis than a 
4+3=7, in which case the most prominent cell type is a 4. The Gleason score goes from 
·2-10, a score 2-4 represents well differentiated cells which would indicate a very low-
3 
grade cancer if present. A Gleason score 5-7 represents moderately differentiated cell 
and yields a slightly worse prognosis, and a score from 8-10 represents poorly 
differentiat.~d cells and signifies high-grade cancer (see Figure 1). 
When there are any abnormalities with the PSA and/or the DRE, a new PSA will 
be tested and if still abnormal a TRUS guided biopsy is obtained. After a complete 
evaluation of the cancer the Pattin table can then be used to determine the chances of the 
cancer metastasizing. It combines the PSA, clinical stage (Tl or T2), and the Gleason 
Score. It was designed to help determine the next appropriate steps or imaging that need 
to occur. When the prostate cancer does progress through the prostatic capsule, the 
( 
cancer cells first metastasize to the seminal vesicles, internal iliac and sacral lymph 
nodes, and then later to the bone. 
Risk Factors 
The physical exam and testing criteria for prostate cancer are fairly standard. 
Men without family history of prostate cancer will start getting DREs and PSAs at the 
age of fifty years old and have a life expectancy of greater than ten years. Those with a 
positive family history for prostate cancer, meaning a first degree relative affected, or of 
the African American race should start being test~d at forty years of age. Prostate 
cancer risk factors and high risk parameters are debatable, there were two studies 
produced one in 1998 by D'Amico et al and the other in"2001 by Zelefsky et aI, which 
support 2 different sets of diagnostic parameters. The D' Amico study, supported high-
risk prostate cancer with a PSA threshold of 20ng/ml, where the ZeIefsky study supported 
a PSA greater than lOng/ml.5, 6 
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There are several studies which look at prostate caneyr due to its prevalence, one 
study looked at a series of autopsy findings where more than 30% of men over fifty had 
cancer in their prostate gland and others have shown prostate cancer exists in ten percent 
of men between the age of twenty a~d forty.7 Another finding from this study was a 
direct relationship between prostate cancer and age. 7 From this study, one could imagine 
that even without the appropriate risk factors (family history or African American) that 
there is a direct correlation with age alone. 
Signs, Symptoms and Diagnosis 
Prostate cancer patient signs and symptoms cover a broad spectrum. Patients with 
the initial stages of prostate cancer are usually asymptomatic and the cancer is detected 
on annual exam with DRE andlor PSA. The use of the DRE alone has been found to be . 
ineffective in about 10% of cases, in which case the PSA value would be the determinate 
to proceed with a biopsy. Also, in the initial stages, patients may complain of bone pain 
and pathologic fractures. As the cancer becomes more advanced and starts to grow 
locally, patients may experience symptoms of outflow obstruction, for example difficulty 
starting and stopping urine, urine retention, and frequent urinary infections secondary to 
incomplete emptying of their bladder, or potentially rectal obstruction. Obstruction of the 
rectum is extremely rare, occurring in about. 1%, due to Denonvilliers' fascia that 
surrounds the prostate and goes between the prostate and the rectum. At this stage the 
DRE may reveal a hard, fixed, asymmetric or possible nodule on the prostate surface. 
Similar symptoms could present with benign prostatic hypertrophy (BPH) or prostatitis. 
If any of these signs or symptoms presented the patient would be further evaluated. 
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Prostate cancer is diagnosed with a combination of DRE and an elevated PSA. 
The American Cancer Society recommends annual DRE and PSA testing for men 50 
years of age and older with a life expectancy of at least ten years, men over 40 years with 
a blood relative who has had prostate cancer and men over the age of 40 who are in high 
risk groups, such as African Americans 7 (see figure 2). 
The development of the PSA test took place with in the last 15 years and has lead 
to a drastic increase in the number of men being diagnOsed with prostate cancer in their 
50's and 60'S.7, 8,9 Previously it was a disease of the elderly man and the cancer was 
more advanc~d, usually a grade Tic, before tumors Were detectable.7,8 PSA is an antigen 
only produced by the prostate gland, in' benign and malignant tissue. The serum PSA 
values correlate with the volume of both types of tissue. PSA testing has advanced the 
date of diagnosis of prostate cancer by at least 5 years. IO The caveat with PSA, is that 
normal PSA values are found in more than 20% of patients with prostate cancer and 
about 20% of patients with abnormally elevated PSA (4ng/ml ...:... lOng/ml) do not have 
prostate cance~ (See figure 3 for normal PSA values broken down by age).8 
Another test being used to detect prostate cancer is the serum-free PSA. Tl1e idea 
behind using free PSA is to potentially decrease unnecessary biopsies in those patients 
with an elevated PSA secondary to BPR In patients with a PSA between 4-10ng/ml, it is 
thought that the probability of developing prostate cancer is 0.25, however if the percent 
free PSA is ~ 17% the probability of cancer increases to 0.45. The free PSAshould not 
be < 20 in those patients with BPR. ll 
The TRUS guided prostate biopsies play an essential role in confirming the 
diagnosis and staging of prostate cancer. When taking biopsies of the prostate, it is 
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broken down into areas or sextants. The tissue samples are then sent to pathology where 
the Gleason score is determined (see Figure 1). · 
Imaging studies used in the workup of prostate cancer include bone scan, CT 
scan, MRI and TRUS. The bone scan, evaluates the presents of bone metastasis, which 
eventually develops in about 80% of patients. Regarding the use of the bone scan, the 
AUA(American Urological Association) does not require that it be used for staging in 
patients who are asymptomatic with clinically localized cancer and a PSA S 20ng/ml. 
The use of CT scan, MRI and TRUS are great in select patients for detection of small 
otherwise undetectable lymph node metastasis. The recommendations for use of CTscan 
and MRI are for those patients with non-localized disease and a PSA >25ng/ml. TRUS 
can be used to confirm the findings of the DRE and/or further evaluate abnormal PSA 
findings. Often biopsies of the prostate are obtained through the guidance of the TRUS if 
either the DRE or the PSA are abnormal. 
Treatment 
There are several treatment modalities available for prostate cancer. The 
treatment we have focused on is Brachytherapy. Some of the other treatments include; 
watchful waiting, radical prostatectomy, external beam radiation, chemotherapy, surgical 
castration <orchiectomy), chemical castration (Lupron, Casadex), and cryotherapy. The 
treatment chosen is dependent on: Stage of the tumor, the patient's life expectancy, 
patients' general medical condition, and patient's treatment preference. 
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Brachytherapy is the use of radioactive seeds of Iodine or Palladiu_m that are 
injected/implanted into the prostate gland which irradiate the gland from the inside. This 
is a fairly non-invasive procedure with few initial side effects. This method is used 
primarily to treatment low grade involvement of cancer in the prostate gland. Some of 
the criteria for permanent seed implant are: Stage TI-T2a, prostate volumeless.thart 60cc 
at the time of implant, PSA less than 10, Gleason less than 6, no significant obstructive 
. symptoms, no perineural or extra-capsular extension or growth, and patient should have 
less than 3 out 6 sextant biopsies positive. However, Brachytherapy can also be used for 
high grade tumors, using a combination of external beam radiation and Palladium seeds. 
The procedure can be approached from: two angles; the first option is to have the . 
. , 
patient come into the operating room where with the use of TRUS · the prostate will 
mapped out in three dimensions. The patient is then sent home. These measurements are 
then given to the radiation oncologist and the physiologist. . They will plan, using 
computer generated images of the prostate, where and how much radiation should be 
applied to each area of the prostate gland, keeping in mind the anatomy and the potential 
damage that the radiation could cause specifically the urethra and rectum. If too many 
seeds or too high of a dose are applied too close to the urethi-a, the patient could suffer 
severe urinary stricture and scarring ot the urethra. This could lead to urinary retention 
and if not correcte~ it could ultimately lead to renal failure. These same seed placement 
considerations also apply to the rectum. The patient would return about four to six weeks 
after the initial measurements were taken for the implantation of the radioactive seeds. 
The other option for patients is to have the TRUS measurements of the prostate 
and implantation occur all with in the same sedation. The process is the same as 
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previously described only the physiologist and the r~diation oncologist are in the 
operating room during the TRUS measurements and the doses are calculated at that time. 
This second technique is often the preferred technique,it only adds about an additional 
thirty minutes on to the procedure, the patient only has to come in once and only has to 
go under anesthesia once. It saves time, discomfort and money for the patient. 
Following both of th~se techniques for implantation of the seeds the urologist 
does cystoscopy looking for seeds or bleeding in the bladder or urethra. Then a Foley 
catheter is place in the bladder through the urethra and left for 3-4 days, to prevent urine 
retention secondary to post-operative swelling of the prostate around the urethra. 
Complications of Brachy Therapy 
Prior to anyone receiving brachytherapy they need to meet the above stated 
criteria as well as had a complete assessment of their functions in regards to pre-implant 
urinary, bowel, and sexual functions. This baseline information is obtained using patient-
completed QOL forms. These forms can then be used as references in evaluating post-
implant morbidities. (See Figures 7 & 8) 
Initial and long term urinary, sexual and rectal symptoms have been reported ~s 
s~.cle-effects of brachytherapy. Some studies have reported tha~ 2%-22% of men will 
develop acute urinary retention postimplantY' 13, 14 Merrick and colleagues in 2001 
found that 88% of men were able to have their urinary catheter permanentlyremoved on 
the day of the surgery, and about 1 % required the catheter for five days post implant. It 
has also been reported that on rare occasion patients need an indwelling catheter or need 
to self-catheterize for several weeks due to 'severe urinary retention. 12 Urinary symptoms 
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are quite variable from patient to patient lasting in some patients up to a couple of years. 
The majority of the initial urinary symptoms are a result of the prostate swelling 
secondary to surgery. One of the most common urinary complaints postoperatively is 
dysuria which can range in intensity. Other early urinary symptoms inClude urinary tract 
infections secondary to patients retaining urine. Another common symptom is hematuria 
J 
for the first few days after the procedure. The recommended treatment for these patients 
is an alpha blocker which causes the smooth muscles of the urinary sphincter to relax, 
improving urinary flow and helping to relieve the symptoms. 
When patients begin experiencing long term urinary symptoms they are often 
caused from the radiation. Late urinary symptoms as ' a result of brachytherapy are 
commonly urethral strictures. Merrick et al in 2001 reported a five year post-treatment 
incidence of urethral strictures at 5%_12%.12. They also found that higher doses of 
radiation to the urethra yielded more patients d~veloping~ strictures.12 Urinary 
incontinence is a rare symptom of brachytherapy unless the patient has had a previous 
trans-urethral resection of the prostate (TURP) or a previous history of such problems. 
Rectal symptoms such as proctitis, bleeding or a change in frequency have been 
known to occur in brachytherapy patients. Studies have found that less than 5% of, 
brachytherapy patients develop radiation-induced proctitis or inflammation of the rectum 
or anus.15, 16 ' Late-onset proctitis has been found to typically occur between the first and 
second year following the implant; patients usually complain of intermittent rectal 
bleeding. Proctitis is usually self-limiting and managed with topical steroids and sitz 
baths. Other more severe rectal complications which are extremely rare are rectal 
ulcerations arid the formation of fistulas. 
10 
o 
Erectile dysfunction (ED) currently affects more than 30 million American men. 
o ED is often a result of the normal aging processes; it can also be caused by trauma, 
neurogenic impairment, vascular compromise and psychogenic causes. A study by 
Merrick et al. determined that 6-61 % ofbrachytherapy patients with or without external 
o 
beam radiation will develop ED.17 In brachytherapy patients, it is very important to 
assess the patients sexual potency before treatment and then serially after. Patients who 
o do develop ED as a result of brachytherapy alone usually recover function with the use of 
one of the ED medications like sildenafil citrate (Viagra, Pfizer Pharmaceuticals). All 
brachytherapy patients need to be thoroughly counseled on ED and given the various 
o 
. treatment options both before and after treatment. 
o Statement of Purpose 
The goals of this study are to assess the symptoms of prostate cancer patient's 
pre- and 5 years post-brachytherapy. I along with ·Dr. Greg McCoy of The Urology 
o Clinic in Portland, Oregon, we will compare the. two sets of data looking to see whether 
the patients' urinary, sexual and rectal symptoms changed. I hypothesize that the 
majority of patients' symptom scores will worsen~by only a small margin. The focus of 
o 
this stu.dy is to answer the following four questions; 
1) General overview of how the entire population handled the treatment; did their 
o urinary, sexual or rectal symptoms improve or get worse? 
2) Which is a better predictor of low and high risk, PSA, Gleason Score, or the 
result of the Partin table of how patients do symptomatically over a 5 year period? 
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3) Is there any significant benefit or loss to patients who receive brachytherapy as . 
a mono-therapy or if they also received either combination of treatments (external 
beam radiation, hormone therapy or a combination of the two)? 
4) Is a there a significant sexual function outcome difference when comparing 
those patients who took ED medications and those who did not take ED 
medications. 
This research will allow the surgeons at The Urology Clinic to better assess their 
patients outcomes. 
Methods 
Population Selection 
This study was a retrospective chart review of 138 patients, who have had 
brachytherapy for prostate cancer between the dates of August 1996 and May 2000. A 
. ! 
brief follow-up survey was sent to all of the 119 surviving patients to assure that their 
most recent data were being evaluated (figure 6). However due to time constraints, the 
data from these surveys will be evalu<,l.ted for Dr. McCoy at a later date. For the purpose 
of this study, all of the data were collected at Legacy Emanuel Hospital in the Advanced 
Urology Center. Dr. Mark Schray, a radiation Oncologist, has developed a database 
looking at all of the Brachytherapy cases performed at Emanuel hospital since the start of 
the brachytherapy program in 1996. A search of the database was performed to narrow 
. the one-thousand plus existing database patients down to the 139 patients whom Dr. 
McCoy performed the Brachytherapy on between the above specified dates. See Table 1 
for patient population. 
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General Information 
Patients were assigned a number and their data were entered anonymously into an 
Excel spreadsheet. The information collected that was applied to this study includes: age 
at implant, Gleason score at implant, clinical stage, other treatments tried, erectile 
medications taken, pre-treatment PSA values, 3 year, and 5 year posHreatn'lent PSA 
values, and pre and post AVA, SHIM, and Rectal symptoms. Data were analyzed 
initially, obtaining a general overview of how the patients PSA changed from at the time 
of treatment (pre-treatment) to 3 and 5 years after treatment, as well as, how the patients 
rated their symptoms pre-treatment vs. post- treatment (See Tables 2 & 3). Vrinary 
symptoms were standardized using the AVA urinary symptoms score form, which ranks 
a patients urinary symptoms on a scale from 0- 35, with a score of 0 being asymptomatic 
and 35 representing the patient haVing severe urinary symptoms. Sexual symptoms were 
standardized using the SHIM form which ranks sexual function from 0 (representing 
patients who are experiencing significant sexual dysfunction) to 25 (patients are 
asymptomatic). The following rectal symptoms were recorded: none, frequency/urgency, 
bleeding, proctitis, diarrhea or other. 
Low vs. High Risk 
After getting an overview of the general population, the patienjs were then broken 
down into Low Risk which is defined as PSA::; 10, Gleason score < 7 and the calculated 
,extra-prostatic extension from the Partin table < 32. The High Risk groups were defined 
as PSA > 10, Gleason Score '2.7 and the calculated extra-prostatic extension from the 
Partin table < 32 (based on a median split)(see Table 4). 
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Statistical Analysis 
Further analysis was restricted to patients that met specific inclusion criteria. To 
be included, patients needed to have 5 year post-treatment PSA values, and a pre-
treatment PSA between O-lOOng/mi. The PSA range was chosen based on the fact that 
patients with advanced disease can have a PSA in excess of 40ng/ml. After these criteria 
were applied the remaining sample size was 88 patients. Of these 88 men the mean age 
at implant (start of treatment) was 67.6 years with youngest being 48 years and the oldest 
79 years old. To calculate improvement in scores for each variable (PSA, ADA), the 
difference between the S yr follow up and the pre-treatment score were utilized. For all 
,variables, assumptions of normality were tested. Statistical , significance Alpha values 
were set at O.OS. SYSTAT 11 software was used for all analyses. 
Results 
General Outcomes 
As part of the general overview, the results of the five year post PSA values were 
addressed (see table 2 and figure 9). Due to patients being lost to follow-up or death, we 
were only able to obtain the five year post-treatment PSA values for 63.8% (n=88) of our 
patients. The S year PSA values improved for most patients in this study (fig 9, table 2). 
Of the 88 patients, only one experienced an increase in PSA from pre-treatment 
(S.2ng/ml) to a five year post-treatment PSA (14.1ng/ml). 
All of the symptoms were looked at by comparing the results of both the pre- and 
post-treatment symptom evaluation forms. In general, after treatment, the majority of 
patients experienced an increase in their ADA scores, the mean pre-treatment ADA score 
14 
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was 7.04 and the mean post-treatment AUA score was i1.52, a difference of 4.48 (see 
o table 3). Graph Band C depict the urinary and sexual outcomes. About a 40% decrease 
in sexual potency was seen post-treatment (table 3). There was a 30% increase in rectal 
symptoms from pre- vs. post-treatment (table 3). 
o 
Low vs. High Risk 
o Due to the fact that brachytherapy is generally used in the treatment of low grade 
prostate cancer,one would imagine that the population would fall mostly within the low 
risk groups. The low risk PSA population comprised 81.8% of the study population. In 
o 
terms of PSA reduction, the low risk group did not experience the largest decrease in 
PSA values that those of the High risk group experienced in the first 3 years; however, 
o both groups managed to experience significant PSA reductions over the 5 year term. 
I 
When risk was categorized based on pre-PSA, Gleason score and extra-prostatic 
extension probability, there were no real differences between the low and high risk 
o groups of AVA scores (low risk mean pre/post AVA= 6.88/11.49 ±1, high risk mean 
pre/post AUA=7.73/U.63 ±1) (see table 4). On the other hand, there did appear to be a 
fairly significant improvement in SHIM scores of patients in both the low and high risk 
o 
groups, but due to the 'difference in population size it is difficult to determine. 
The rectal symptoms in the low risk group, due to the larger population, were 
o more varied. The post-rectal symptom data supported the development of bleeding in 1-
2% of the low risk group and about 6% in the high risk group. The development qf 
proctitis occurred in the low risk group in about 11 % and 12% in the high risk group of 
o 
patients. However, most of these cases start within the first year following treatment, but 
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it was unclear from the data at what point this symptom resolved. It was difficult to 
determine from the results whether PSA or Gleason score was a better determinate for 
how patients would tolerate the treatment. (Low vs. High PSA: Chi-square=3.145, df=l, 
p=0.076; Gleason: Chi-square=0.006, df=l, p=0.936). 
The probability of developing extra-prostatic extension was the last risk variable 
assessed. The high and low risk groups were determined based on a median split of the 
population which gave us 32. To depict extra-prostatic extension vs. SHIM: a 
nonparametric analyses (Mann-Whitney U) was used, (see figure 12) and the results 
appeared to be significant (Mann-Whitney U = 1120.50, p=0.017). The data for 
extension and AUA again showed a similar increase in AUA post-treatment. There was 
no difference between the low and high risk groups in terms of the rectal symptoms. 
. Mono- vs. Multi-therapy 
The addition of other therapies did not yield an . obvious benefit over mono-
therapy (see table 5). The use of a two-sample t-test, looking at the effect of mono-
therapy versus multiple therapie~, found rio significant difference between the two groups 
of patients (t=0.007, df=75, p=0.995). Using the same statistical tests we looked at how 
the PSA was affected in the two groups and this showed a significant difference (t=2.783, 
df=85, p=O.007). Those patients in the multi-therapy group experienced a greater 
decrease in PSA values compared to the mono-therapy group. We also performed a 
Mann-Whitney U test on this same set of patients which gave a p=0.006, helping to 
verify the validity of the data. 
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Sexual function was also analyzed looking to see how it was affected by the type 
of therapy, specifically whether the patients experienced an improvement or no 
improvement of their sexual symptoms. Due to the use of two sets of categorical data, 
we used a Pearson chi-square test, which showed a significant effect from multi-therapy 
(Chi-square=4.420, df=l, p=0.036): 
Erectile Dysfunction Medications 
Due to the nature of brachytherapy, sexual function can be at risk, and as a result, 
. men are given ED medications (Viagra, Cialis, Levitra). In the case of this study, about 
20% (n=18) of the study population was admittedly taking one of these medications. A 
Chi-squared test was used to see if those who took the ED medications reported any 
significant improvement of sexual function over those who did not take the medications. 
There were no significant differences in outcomes between patients who took ED 
medications and those who did not (chi-square=2.156, df=l, p=O.142). 
Conclusions 
The treatment of prostate cancer with the use of brachytherapy, in this study has 
been shown to yield minimal risk in regards to patients developing urinary, sexual and 
rectal symptoms. As shown in table 2 the passing rate for the 138 patients who Dr. 
McCoy treated between the dates of August 1996 and May of 2000, was 85.5%. For a 
. patient to pass the procedure, m~ans that they have not had more than 3 consecutive rises 
in their PSA. 
" 
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The general outcome of this study population resulted in 98.9% of the 88 study 
patients to have a decrease in their PSA, 20-40% increase in ADA scores, about a 20% 
improvement in SHIM scores and about 25% of the patients developed rectal symptoms 
with 11-12% of those as proctitis. From this we can 90nc1ude that patients are more 
likely to develop urinary symptoms post brachytherapy than ED, or rectal symptoms. 
Please note that the time of development of rectal symptoms was difficult to determine 
from the database, however it is known that the symptoms were being experienced for at 
least one year post treatment and longer. This information is being collected in the 
survey which will be addressed in the follow-up study due to time constraints. 
When the patients were divided into Low and High Risk groups by PSA, Gleason 
score, and then by probability of developing extra-prostatic extension, calculated from 
. the Partin Table, there was no significant difference between the PSA and Gleason score 
however there does tend to be a trend for the high risk groups to improve more than 
expected by random error. The use of extra-prostatic ex.tension does prove to be an 
indicator of potency. 
Along these same lines, there did not appear to be any real advantage to those 
patients who received external beam, hormone therapy or a combination of the two along 
with brachytherapy ver:sus those who just received brachytherapy as a mono therapy . . 
Other studies have found that brachytherapy as a mono-therapy has a cure rate of 
88-96% in low risk patients and as high as 82% in intermediate risk patientsY' 18. 19 
Another studied found a 76-80% 5-7 year disease free survival rate in high risk patients 
who received external beam radiation followed by brachytherapy.2o 
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There are many alternative studies that could be applied to this topic. Looking at 
age at implant or prostate volume or repeating a similar' study in another five years and 
compare the five year data to the ten yyardata in terms of outcome and possible survival .. 
The options are extensive and there is a lot that has not been researched. 
\ 
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Figure 1 
Gleason Pattern Score 
. Score 
2-4 
5-7 
8-10 
Appearance 
Well Differentiated 
Moderately Differentiated 
Poorly Differentiated 
Figure 2 
The American Cancer Society recommends annual PSA testing for: 
0 men 50 and older with a life expectancy of at least 10 years ' 
0 men over 40 with blood rdatives who have had prostate cancer 
0 men over 40 who are in high-risk groups, such as African Americans 
Figure 3 
A Mayo Clinic study determined that since benign prostatic hyperplasia (EPR) yields 
higher PSAs than the normal level of 4.0 ng/mI, older men will more likely have higher 
norIl).al PSAs than younger men. 
Age PSA Level (ng/mI) 
40-49 2.5 
50-59 3.5 
60-69 4.5 
70-79 6.5 
Adapted From: http://www.u1?mccancercenters.com!cancer/prostate/psa.html 
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Figure 4 
T S umor 
T Stages 
TX 
TO 
T1 (A) 
Tla (AI) 
Tlb'(A2) 
TIc 
TI (B) 
TIa (BI) 
TIb (B2) 
tagmg 
Primary tumor cannot be assessed. 
No evidence of primary tumor. 
Tumor not clinically apparent. 
Tumor incidentally found in <= 5% of prostate sample. 
Tumor incidentally found in > 5% of prostate sample. 
Tumor identified at needle biopsy performed to investigate PSA elevation. 
Tumor palpable and confined to prostate. 
Tumor involves one prostate lobe. 
Thmor involves both prostate lobes. 
T3 (CI - tumor < 6 em) 
Tumor palpable and extends beyond prostate capsule. 
T3a (CI) Thmor extends beyond prostate capsule, either on one side (unilaterally) or both sides (bilaterally). 
T3b(CI) 'Thmor invades seminal vesicles. 
T4 (C2). Thmor is 'fixed or invades adjacent anatomy other than seminal vesicles: bladder neck, external 
sphincter, rectum, levator muscles, and/or pelvic wall. 
N Stages 
Nx Tests to detect lymph node spread have not been done. 
NO Cancer has not spread to any lymph nodes. 
NI (01) Spread to nearby lymph node in the pelvis 
MStages 
Mx Tests to detect distant spread have not been done. 
MO Cancer has not spread beyond the regional nodes. 
MI (D2) Cancer has spread to distant sites. 
MIa (D2) Cancer has spread to distant lymph nodes. 
MIb (02) Cancer has spread to bone(s). 
MIc (02) Cancer has spread to other areas such as lungs, liver, or brain. 
Adapted from: http://medstat.med.utah.edufWebPathfTUTORIALIPROSTATE 
Figure 5 
American Urological Society Clinical Staging (ABCD System) 
Stage Definition IO-vear Survival 
Al Incidental, <5% pfvolume 93-98% 
A2 Incidental, >5% of volume, or high grade 50% 
B I Palpable nodule in one lobe but <1.5 em in diameter 70-75% 
B2 Larger palpable nodule' 62% 
Cl Invades capsule of prostate 40-50% 
C2 Invades seminal vesicle , , 33-39% 
Dl Metastases to regional lymph nodes, or extensive regional spread 17-20% 
02 Evident distant metastases <10% 
Adapted From: . 
http://m:edstat.med.utah.edulWebPathITUTORIALIPROSTATEIPROSTATE. 
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Figure 6 
Survey and Letter of Consent: 
Dear Brachytherapy Patient, 
As we continue to try to optimize the treatment of prostate cancer, it is important to 
gather data regarding patient outcomes and progress. We have been using Brachytherapy 
since 1996 in Portland, and have been impressed by the excellent results in terms of 
achieving local control of prostate tumors. I have asked Ian McMillan, a physician 
assistant student at Pacific University, to contact our patients by way of this short survey 
to assure that we have the most current health information relating to your prostate _ 
treatment. The information collected is confidential. 
Please Circle the most appropriate response and return by July 31,2005. Thank you very 
much. We appreciate your time and honesty. 
Brachytherapy Survey 
History: 
Name: ____________ ~ __ ~ ______________ ~ __ ~ 
Date of Birth: ______ ' 
Phone number: ________ (in case we need clarification) 
1) Do you have a first degree relative (father, brother) with prostate cancer? 
YES NO (Circle One) 
Treatment: . 
2) Was brachytherapy (radioactive seed implantation) the ONLY treatment used? 
YES NO (Circle One) 
If NO, circle other treatments tried: 
A) 
B) 
C) 
D) 
E) 
F) 
G) 
H) 
External Beam Radiation 
·Chemotherapy 
Surgical Castration (Orchiectomy) 
Chemical Castration (Lupron, Zoladex, Casodex) 
If yes to "D", how long did you receive this therapy? ' ________ _ 
Cryotherapy 
Transurethral Microwave Thermotherapy 
Radical Retropubic Prostatectomy 
Other: ____________________ _ 
3) What type of seeds were implanted? (iodine or palladium) 
4) What was your most recent PSA result? _______ ' 
5) What was the date ofPSA? (approximately) -'--___ _ 
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Urinary Symptoms: 
6) Did you experience bothersome urinary symptoms prior to treatment? 
1) 
8) 
9) 
10) 
YES NO (Circle One) 
If YES, circle all symptoms that apply: daytime frequency, nighttime frequency, 
iJrgency, leakage, weak stream, difficulty starting or stopping stream, , 
other: ________ _ 
Are you currently experiencing bothersome urinary symptoms? 
YES NO (Circle One) 
If YES, circle all symptoms that apply: daytime frequency, nighttime frequency, 
urgency, leakage, weak stream, difficulty starting or stopping stream, 
other: 
---------
If you required taking alpha blockers (Flomax (tamsulosin); Uroxatrol (alfuzosin), 
Cardura (doxazosin), Hytrin (terazosin) following the procedure, how long did 
you take them and specifywhich one(s)? ____________ _ 
Do you still take any of these drugs for your urinary symptoms? __ ----
., 
Did you require any anticholinergic medication (Detrol (tolterodine), Ditropan xl 
(oxybutynin), Oxytrolpatches)? If yes which ones? __________ ' 
Are you still using any of these medications? If yes which ones? _____ _ 
Did you develop urinary retention at any time, requiring replacement of a catheter 
into you bladder? Please give details. __________ -----
11) Did you require any urologic procedure after seed implant such as dilation of a 
stricture or cystoscopy for bleeding, either in the office or in the hospital? Please 
elaborate. ________________________ _ 
Sexual Function: ",' 
12) Have you used medication or a device to help acquire and maintain an erection 
either before or after treatment? Please Specify: __________ _ 
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13) 
14) 
15) 
Prior to treatment how would you rank the quality of your erections? 
1 = No Erection 
2 = Erection NOT rigid enough for vaginal penetration. 
3 = Firm Erection, able to penetrate (enter partner) without difficulty. 
If you used medication (Viagra (sildenafil), Cialis (tadalafil), Levitra (vardenafil), 
Caverject (alprostadil» or device (vacuum, penile implants) to help acquire and 
maintain an erection? Please specify: _______________ _ 
Since being treated have you noticed' any change in the quality of your erections? 
YES NO' (Circle One) 
If you used medication (Viagra (sildenafil), Cialis (tadalafil), Levitra (vardenafil), 
Caverject (alprostadil)) or device (vacuum, penile implants) to help acquire and 
maintain an erection? 
Please Specify: ____________________ _ 
Following the treatment how would you rank the quality of your erections? 
1 = No Erection 
2 = Erection NOT Rigid enough for vaginal penetration. 
3 = Firm Erection, able to penetrate without difficulty. 
Bowel Habits: 
16) Did you experience any bowel problems prior to the treatment? _____ _ 
17) 
Circle your ~-treatment rectal symptoms: none, urgency, bleeding, frequency, 
fistula, diarrhea, stricture, abscess, proctitis 
How bothersome were your bowel symptoms prior to treatment on a scale from 
1-10? ___ _ 
Have you experienced any change in bowel habits since the treatment? 
C~rc1e your post-treatment rectal symptoms: none, urg~ncy,bleeding, 
frequency, fistula, diarrhea, stricture, abscess, proctitis 
How bothersome were your bowel symptoms after treatment on a scale from 
C 1-1O? __ _ 
C) 
18)' Have the symptoms resolved? ____ _ 
19) 
If not, how severe are they now? _____ _ 
Did you require any 'treatment or procedures (colonoscopy) for your bowel 
symptoms? 
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Quality of Life: 
20) . Quality of life BEFORE treatment: 
Circle one of the following: 
.1= Not Happy 
2= Could Be Better 
3= Could Be Worse 
4= Satisfied 
5= Very Satisfied 
Thanks again for your time and honesty. 
Sincerely, 
Gregory B. McCoy, MD 
Quality of life AFTER treatment: 
Circle one of the following: 
1= Not Happy 
2= Could Be Better 
3= Could Be Worse 
4= Satisfied 
5= Very Satisfied 
Ian McMillan, P A-S 
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Brachytherapy Patient Follow-Up 
PSA Levels 
Date 
Level 
Ifno current PSA level is available, please list the Name and Phone Number ofthe primary 
physician involved with caring for your prostate cancer. 
AVA Score 
~~ , ~ .... ~1tJ ~'b' 
• ~ 1><:- ~ 1><:- ItJ ~ 1><:- ° !<.. ~ ',,," ~-<"~ ~'<:' ~-<.~ t} ~~ ~~ 4'!J ~1tJ r:.~ ItJ 0" ~1tJ ~1tJ ~o ~~ 
yO -<." yO ~ ~ -<.' ~o ~1tJ ~ ~ 
0 1 2 3 4 5 
0 1 2 3 4 5 
0 1 2 L 3 4 5 
0 1 2 3 5 
o· 1 2 3 5 
0 1 2 3 4 5 
Please Total the Numbers You Circled 
Please use the following to provide feedback, i.e. urinary problems, sexual dysfunction, 
rectal problems, or any other problem you feel may have been caused by treatment. Any 
other feedback is welcome as well. 
Please see reverse side, Page 1 of 2 
.--------- -- - - --- ... -.. ~.- -------,~-.--. - - --------- --- . . 
Figure 8 
SHIM Score Form 
o 
o 
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REGIONAL CENTER ' ' ADVANCED UROLOGY 
Sexual Health Inventory for Men 
Name: Date: 
--------------------
Erectile dysfunction, also known as impotence, is one type of very common condition affecting sexual 
health. This questionnaire is designed to help you and your doctor identify, if you may be experiencing 
C' erectile dysfunction. If you are, you may choose to discuss treatment options with your doctor. 
o 
o 
o 
o 
o 
o 
Each question has several possible responses. Circle the number of the response that best describes your 
own situation. Please be sure that you select one and only one response for each question. 
Over the past six months: 
A. How do you rate your confidence that 
you could get and keep an erection? 
VeryLow 1 
Low 2 
Moderate 3 
High 4 
Very High 5 
B. When you had erections with sexual 
stimulation, how often were your erections 
hard enough for penetration (entering 
your partner)? 
No sexual activity 0 
Almost never or never 1 
Few times (much less than halfthe time) 2 
Sometimes (about half the time) 3 
Most times (much more than halfthe time) 4 ' 
Almost always or always 5 
C. During sexual intercourse, how often 
were you able to maintain your erection 
after you had penetrated (entering your 
partner)? 
Did not attempt intercourse 0 
Almost never or never 1 
Few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than halfthe time) 4 
Almost always or always 5 
501 N. Graham, Suite LL 165 
. Portland, Oregon 97227 
D. During sexual intercourse, how, 
difficult was it to maintain your ereCtion 
to completion of intercourse? 
Did not attempt intercourse 0 
Extremely difficult 1 
Very difficult 2 
Difficult 3 
Slightly difficult 4 
Not difficult 5 
E. When you attempted sexual intercourse, 
how often was it satisfactory for you? 
Did not attempt intercourse 0 
Almost never or never 1 
Few times (much less than half the time) 2 
Sometimes (about half the time) 3 
Most times (much more than half the time) 4 
Almost always or always 5 
Total Score: 
--------
503-413-1145 
503-413-4651 FAX 
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Figure 9 
General Population: A look at how 
much PSA improved post-treatment. 
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Figure 11 
General Population: Did SHIM scores, 
improve, stay the same or get worse? 
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Figure 13 
Was there a significant difference in regards to AUA 
scores between those who received Brachytherapy as 
Figure 14 
a mono-therapy or multi-therapy? 
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Mono-therapy vs. Multiple treatments 
Was there a significant difference in regards to a 
change in PSA between those who received 
Brachytherapyas a mono-therapy or multi-therapy? 
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Table 1 
Patient Demographics 
Window for Treatment Dates Table 2. 
4/1996-5/2000 Comparison of PSA before treatment to 
0 Patient Demographics 3 and 5 years post treatment. (Numbers based on 138 Patients) Pre-Tx PSA (nglml) 
Number Patients 138 
Total Patients 138 Average Pre PSA 8.97 
Number Surviving 119 Median Pre PSA 7.10 
Number Dead 19 Range Pre PSA 0.S9-140.0 
O-S.O 30 (21.7%) 
0 Cause of Death 5.1-10.0 76 (%) 
-" PC Present 9 10.1-20.0 28 (15.2%) 
Unknown 1 >20 4 (2.2%) 
+PC 1 
PC PresentINot Cause 2 
Other 6 3 yr Post-Tx PSA (nglm1) 
Male 100% Number Patients 124 
0 Age at Implant Average Post PSA 0.68 
Mean 68 years Median Post PSA 0.10 
Median 69 years Range Post PSA " 0-15 
Range 48-80 years 0-5.0 121 (97.6%) 
Gleason Score 5.1-10.0 0 
%<6 45 (32.6%) 10.1-20.0 3 (2.4%) 
%=6 74 (S3.6%) >20 0 
0 %>6 19 (13.8%) 
Clinical Staging 
Tic 63 (4S.7%) 5 yr Post-Tx PSA (nglm1) 
T2a" 45 (32.6%) Number Patients 88 
T2b 18 (13.0%) Average Post PSA 0.46 
T2c 10 (7.2%) Median Post"PSA 0.10 
T3 1 (0.7%) Range Post PSA 0-14.1 
CJ ? 1 (0.7%) 0-5.0 87 (98.9%) 
Isotopes 5.1-10.0 0 
1-125108 Gy 3 (2.2%) 10.1-20.0 1 (1.1 %) 
1-125 144 Gy 90 (65.2%) >20 0 
Pd-103 128 Gy 3 (2.2%) 
Pd-103 90 Gy 36(26.1%) 
? 6 (4.3%) Failed Treatment 0 Prostate Gland Size (cc) 3 consecutive rises in PSA 17 
Average 36.S3cc Died 3 
Median 36.40cc Passed Treatment 118 (85.5%) 
Range 14.4-S9.9cc 
% + Biopsy 
Average 36.77% 
Median 33.3% 
CJ Range 7.7-100% 
Other Treatments 
Ext Beam 27 (19.6%) 
Hormone 35 (25.4%) 
Hormone/Ext Beam 17 (12.2%) 
Mono-therapy 59 (42.8%) 
CJ 
o 
o 
o 
o 
o 
o 
Table 3 
Symptoms scores of study population. 
Overall Symptoms (Numpers based on 88 Patients) 
PreAUA 
Post AUA 
Pre SHIM 
Post SHIM 
Pre Rectal 
Post Rectal 
mean =7.04 
mean = 11.52 
median = 5 
median = 11 
<5 (n=19, 21.6%) 
>5<15 (n=14, 15.9%) 
>15 (n=55, 62.5%) 
<5 (n=39; 44.3%) 
>5<15 (n=25, 28.4%) 
>15 (n=20, 22.7%) 
? (n=4,4.5%) 
No C/O (n=87, 98.9%) 
Frequency (n=I, 1.1 %) 
No C/O (n=59, 67.0%) 
Bleeding (n=8, 9.1 %) 
Bleeding/Proctitis (n=2,2.3%) 
Bleeding/Diarrhea (n=3, 3.4%) 
Proctitis (n=13, 14.8%) 
Proctitis/Urgency (n=l, 1.1%) 
"Rectal problems" (n=2, 2.3%) 
o 
o 
o 
o 
o 
o 
o 
o 
o 
c ) 
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Table 4 Results of Symptoms in Low vs. High Risk Patients. (RG=Risk Group, 
TP=Total Population (n=88)) 
Low Risk 
PSA ~ 10 (81.8% of Study Population) 
Pre PSA (n=72) mean = 6.06 
3yr Post PSA(n=72) mean = 0.59 
5yr Post PSA(n=72) mean = 0.41 
median = 5.95 
median = 0.15 
median = 0.10 
PreAUA 
Post AUA 
Pre SHIM 
Post SHIM 
Pre Rectal 
Post Rectal 
Low Risk 
mean = 6.88 
mean = 11.49 
median = 5 
median = 11 
<5 (n=18, 25%RG, 20.5%TP) 
>5<15 (n=10, 13.9%RG,11.4%TP) 
>15 (n=44, 61.1 %RG, 50%TP) 
<5 (n=34, 47 .2%RG, 38.6%TP) 
>5<15 (n=15, 20.8%RG, 17%TP) 
>15 (n=19, 26.4%RG, 21.6%TP) 
? (n=4, 5.6%RG, 4.5%TP) 
No C/O (n=71 , 98.6%RG, 80.7%TP) 
Frequency (n=I,1.4%RG, 19.3%TP) 
No C/O (n=48, 66.7%RG, 54.5%TP) 
Bleeding (n=7, 9.7%RG, 7.9%TP) 
Bleeding/Proctitis (n= I, 1.4%RG, 1.1 %TP) 
Bleeding/Diarrhea (n=l, 1.4%RG, 1.1 %TP) 
Bleeding/Urgency (n=l, 1.4%RG, 1.1%TP) 
Proctitis (n=10, 13.9%RG, 11.4%TP) 
Proctitis/Urgency (n=l, 1.4%RG, 1.1 %TP) 
"Rectal problems" (n=2, 2.8%RG, 2.3%TP) 
Gleason <7 (n:;;;77, 87.5% of Study Population) 
0=4 (n=22, 28.6%RG, 25%TP) 
G=5 (n=12, 15.6%RG, 13.6%TP) , 
. G=6 (n=43, 55.8%RG, 48.9%TP) 
Pre AUA (n=77) mean = 6.99 
Post AUA (n=77) mean = 11.54 
median = 4.5 
median = 11 
Pre SHIM 
Post SHIM 
Pre Rectal 
Post Rectal 
<5 (n=18, 23.4%RG, 20.5%TP) 
>5<15 (n=l1, 14.3%RG, 12.5%TP) 
>15 (n=48, 62.3%RG, 54.5%TP) 
<5 (n=34, 44.2%RG, 38.6%TP) 
>5<15 (n=23, 29.9%RG, 26.1 %TP) 
>15 (n,,=,17, 22.1%RG, 19.3%TP) 
? (n=3, %) 
No C/O (n=76, 98.7%RG, 86.4%TP) . 
Frequency (n=l, l.3%RG, 1.1 %TP) 
No C/O (n=51, 66.2%RG, 56.0%TP) 
Bleeding (n=8, 10.4%RG, 9.1%TP) 
Bleeding/Urgency (n=2, %) 
Proctitis (n=12, %) 
Proctitis/Urgency (n=l, %) 
. "Rectal Problems" (n=l, %) 
High Risk . 
PSA >10 (18.2% of Study Population) 
Pre PSA (n=16) mean = 15.17 median = 13.5 
median = 0.18 
median = 0.06 
3yr Post PSA(n=16) mean = 0.47 
5yr Post PSA(n=16) mean = 0.69 
PreAUA 
PostAUA 
Pre SHIM 
Post SHIM 
Pre Rectal 
Post Rectal 
High Risk 
mean = 7.73 
mean = 11.63 
median = 5 
median = 11.5 
<5 (n=l, 6.3%RG, 1.1 %TP) 
>5<15 (n=4, 25%RG, 4.5%TP) 
>15 (n=l1, 68.7%RG, 12.5%TP) 
<5 (n=5, 31.3%RG, 5.7%TP) 
>5<15 (n=lO, 62.5%RG, 11.4%TP) 
>15 (n=l, 6.3%RG, 1.1 %TP) 
No C/O (n=16, lOO%RG, 18.2%TP) 
No C/O (n=l1, 68.7%RG, 12.5%TP) 
Bleeding (n=l, 6.3%RG, 1.1 %TP) 
Bleeding/Proctitis (n= I, 6.3%RG, 1.1 %TP) 
Proctitis (n=3, 18.8%RG, 3.4%TP) 
Gleason '2,7 (n=l1, 12.5% of Study Population) 
0=7 (n=7, 63.6%RG, 8.0%TP) 
G=8 (n=4, 36.4%RG, 4.55%TP) 
Pre AUA (n=l1) mean = 7.36 
Post AUA (n=l1) mean = 11.36 
median:;;; 6 
median = 12 ' 
Pre SHIM 
Post SHIM 
Pre Rectal 
Post Rectal 
<5 (n=2, 18.2%RG, 2.3%TP) 
>5<15 (n=3, 27.3%RG, 3.4%TP) 
>15 (n=6, 54.5%RG, 6.8%TP) 
<5 (n=5, 45.5%RG, 5.7%TP) 
>5<15 (n=2, 18.2%RG, 2.3%TP) 
>15 (n=3, 27.3%RG, 3.4%TP) 
? (n=l, 9.1 %RG, 1.1 %TP) 
No C/O (n=l1, 100%RG, 12.5%TP) 
No C/O (n=8, 72.7%RG, 9.1 %TP) 
Bleeding/Proctitis (n=l, 9.1%RG, l.1%TP) 
BleedinglDiarrhea (n=l, 9.1 %RG, 1.1 %TP) 
Proctitis (n=l, 9.1%RG, 1.1%TP) 
o 
o 
o 
o 
o 
o 
o 
o 
o 
Table 4 (Low vs. High Risk) Cont. 
Extra-prostatic extension calculated from Partin Table 
Low Risk <32 (n=43, 48.9%TP) 
Pre AUA (n=40) mean = 7.05 
Post AUA (n=42) mean = 11.05 
median = 5 
median=9.5 
Extra-prostatic extension calculated from Partin Table 
High Risk ?,32 (n=45, 51.1 %TP) 
Pre ADA (n=41) mean = 7.02 
Post ADA (n=43) mean = 11.98 
median =5 
median = 11 
Pre SHIM <5 (n=12, 27.9%RG, 13.6%TP) Pre SHIM <5 (n=7, 15.6%RG, 8.0%TP) 
>5<15 (n=lO, 22.2%RG, 11.4%TP) 
>15 (n=27, 60.0%RG, 30.7%TP) 
<5 (n=21 , 46.7%RG, 23.9%TP) 
>5<15 (n=17, 37.8%RG, 19.3%TP) 
>15 (n=4, 8.9%RG, 4.5%TP) 
Post SHIM 
Pre Rectal 
Post Rectal 
Table 5 
>5<15 (n=4, 9.3%RG, 4.5%TP) 
>15 (n=27, 62.8%RG, 30.7%TP) 
<5 (n=18, 41.9%RG, 20.5%TP) Post SHIM 
>5<15 (n=8,J8.6%RG, 9.1%TP) 
>15 (n=17, 39.5%RG, 19.3%TP) 
No C/O (n=43, 100%RG, 48.9%TP) 
No C/O (n=31 , 72.1 %RG, 35.2%TP) Pre Rectal 
Bleeding (n=4, 9.3%RG, 4.55%TP) 
Proctitis (n=5, 1l.6%RG, 5.7%TP) Post Rectal 
Proctitis/Urgency (n=l, 2.3%RG, 1.1 %TP) 
? (n=3, 6.7%RG, 3.4%TP) 
No c/o (n=44, 97.8%RG, 50%TP) 
Frequency (n;"1, 2.2%RG, l.1%TP) 
No C/O (n=28, 62.2%RG, 31.8%TP) 
Bleeding (n=4, 8.9%RG, 4.5%TP) 
BleedinglUrgency (n=3, 6.6%RG, 3.4%TP) 
Proctitis (n=8, 17.8%RG, 9.1 %TP) 
Proctitis(Bleedin~ (n=2, 4.4%RG, 2.3%TP) 
Comparing the symptoms of those patients who received brachytherapy as a mono-
therapy to· those patients who also received extern beam radiation, hormone or both 
extern beam and hormone therapies. 
Mono- Ext-
therapy Beam Hormone Combined 
n= 39 18 16 15 
x Gleason 5.26 6.1 5.18 6.0 
x Pre-PSA 5.9 10.17 7.39 9.76 
x 3yr PSA 0.36 0.27 0.42 1.65 
x 5yr PSA 0.22 0.47 0.25 1.3 
x Pre-AUA 6.23 8.5 5.44 9.21 
x Post-AU A 11.0 14.41 8.53 12.53 
Pre-SHIM <5 8 :1 5 5 
>5<15 5 4 2 3 
>15 26 13 9 7 
Post-SHIM <5 14 8 8 9 
>5<15 8 6 6 4 
>15 15 2 2 1 
Pre-Rectal No C/O 39 17 16 15 
Freq 0 1 0, 0 
Post-Rectal No C/O 28 9 14 9 
Bleeding 6 2 0 1 
Proctitis 4 2 2 5 
(\ 
(j 
o 
o 
o 
o 
o 
o 
o 
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